Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Other financing activities (2017 - 2025)

Historic Other financing activities for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $5.7 million.

  • Protagonist Therapeutics' Other financing activities fell 5304.12% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 695.7%. This contributed to the annual value of $26.5 million for FY2024, which is 45410.56% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Other financing activities stood at $5.7 million for Q3 2025, which was down 5304.12% from $2.9 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Other financing activities high stood at $12.1 million for Q3 2024, and its period low was -$2.3 million during Q1 2023.
  • Its 5-year average for Other financing activities is $3.0 million, with a median of $1.4 million in 2021.
  • In the last 5 years, Protagonist Therapeutics' Other financing activities crashed by 18838.94% in 2023 and then skyrocketed by 108031.34% in 2024.
  • Protagonist Therapeutics' Other financing activities (Quarter) stood at $2.3 million in 2021, then tumbled by 76.36% to $553000.0 in 2022, then decreased by 6.15% to $519000.0 in 2023, then soared by 676.69% to $4.0 million in 2024, then skyrocketed by 40.39% to $5.7 million in 2025.
  • Its Other financing activities stands at $5.7 million for Q3 2025, versus $2.9 million for Q2 2025 and $11.9 million for Q1 2025.